Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phosphodiesterase inhibitors.

Victoria Boswell-Smith1, Domenico Spina, Clive P Page

  • 1Sackler Institute of Pulmonary Pharmacology, Kings College London School of Biomedical Health and Life Sciences, 5th Floor, Hodgkin Building, Guys Campus, Kings College, London SE1 1UL, London.

British Journal of Pharmacology
|January 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nebulised heparin as a treatment for lung diseases: formulation challenges and pulmonary drug delivery strategies.

Lung·2026
Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026
Same author

The Platelet/Megakaryocyte Axis is Necessary for Allergic Sensitisation and Inflammatory Responses to House Dust Mite in the Lung.

Lung·2026
Same author

The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung.

Lung·2026
Same author

Platelet-specific P2Y<sub>1</sub> receptor deficient mice have suppressed pulmonary leukocyte recruitment in response to lipopolysaccharide.

Respiratory research·2026
Same author

Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.

Respiratory research·2025

Phosphodiesterase (PDE) inhibitors are crucial for treating various diseases. This review highlights the development of specific PDE inhibitors for heart failure, inflammatory lung disease, and erectile dysfunction.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Phosphodiesterases (PDEs) regulate intracellular cyclic nucleotide levels (cAMP, cGMP), impacting cell function.
  • Historically used drugs like theophylline and papaverine weakly inhibit PDEs, with unclear clinical contribution.
  • Discovery of 11 PDE isoenzyme families necessitates selective inhibitors for targeted therapies.

Purpose of the Study:

  • To review the development of isoenzyme-selective phosphodiesterase inhibitors.
  • To focus on PDE3 inhibitors for congestive heart failure.
  • To examine PDE4 inhibitors for inflammatory airways disease and PDE5 inhibitors for erectile dysfunction.

Main Methods:

  • Literature review of phosphodiesterase research.
  • Analysis of therapeutic applications of PDE inhibitors.

Related Experiment Videos

  • Focus on isoenzyme-specific inhibitor development.

    • Main Results:

    • Significant progress in developing PDE inhibitors for specific diseases.
    • PDE5 inhibitors have shown notable success in treating erectile dysfunction.
    • Ongoing research targets PDE3 and PDE4 inhibitors for heart failure and inflammatory airways diseases, respectively.

    Conclusions:

    • Isoenzyme-selective PDE inhibitors represent a promising therapeutic strategy.
    • Targeting specific PDE families offers potential for treating diverse medical conditions.
    • Further research into PDE isoenzymes will drive the development of novel therapeutics.